Annual CFO
-$95.21 M
+$61.11 M+39.09%
December 1, 2024
Summary
- As of March 12, 2025, ADPT annual cash flow from operations is -$95.21 million, with the most recent change of +$61.11 million (+39.09%) on December 1, 2024.
- During the last 3 years, ADPT annual CFO has risen by +$97.52 million (+50.60%).
- ADPT annual CFO is now -146.35% below its all-time high of $205.40 million, reached on December 31, 2019.
Performance
ADPT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$12.49 M
+$14.57 M+53.85%
December 1, 2024
Summary
- As of March 12, 2025, ADPT quarterly cash flow from operations is -$12.49 million, with the most recent change of +$14.57 million (+53.85%) on December 1, 2024.
- Over the past year, ADPT quarterly CFO has increased by +$14.57 million (+53.85%).
- ADPT quarterly CFO is now -104.49% below its all-time high of $278.30 million, reached on March 31, 2019.
Performance
ADPT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$95.21 M
+$14.44 M+13.17%
December 1, 2024
Summary
- As of March 12, 2025, ADPT TTM cash flow from operations is -$95.21 million, with the most recent change of +$14.44 million (+13.17%) on December 1, 2024.
- Over the past year, ADPT TTM CFO has increased by +$14.44 million (+13.17%).
- ADPT TTM CFO is now -137.76% below its all-time high of $252.14 million, reached on March 31, 2019.
Performance
ADPT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ADPT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.1% | +53.9% | +13.2% |
| 3 y3 years | +50.6% | +73.5% | +54.4% |
| 5 y5 years | -146.3% | +73.5% | +54.4% |
ADPT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.6% | at high | +80.6% | at high | +54.4% |
| 5 y | 5-year | -146.3% | +50.6% | at high | +80.6% | -146.3% | +54.4% |
| alltime | all time | -146.3% | +50.6% | -104.5% | +80.6% | -137.8% | +54.4% |
Adaptive Biotechnologies Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$95.21 M(-39.1%) | -$12.49 M(-53.8%) | -$95.21 M(-13.2%) |
| Sep 2024 | - | -$27.07 M(+56.4%) | -$109.65 M(-15.2%) |
| Jun 2024 | - | -$17.30 M(-54.9%) | -$129.27 M(-4.6%) |
| Mar 2024 | - | -$38.35 M(+42.4%) | -$135.53 M(-13.3%) |
| Dec 2023 | -$156.32 M(-15.0%) | -$26.93 M(-42.3%) | -$156.32 M(-1.9%) |
| Sep 2023 | - | -$46.68 M(+98.2%) | -$159.41 M(+2.8%) |
| Jun 2023 | - | -$23.56 M(-60.2%) | -$155.13 M(-13.2%) |
| Mar 2023 | - | -$59.15 M(+97.0%) | -$178.64 M(-2.9%) |
| Dec 2022 | -$183.94 M(-4.6%) | -$30.02 M(-29.2%) | -$183.94 M(-11.5%) |
| Sep 2022 | - | -$42.41 M(-9.9%) | -$207.75 M(-0.5%) |
| Jun 2022 | - | -$47.06 M(-27.0%) | -$208.79 M(+5.0%) |
| Mar 2022 | - | -$64.45 M(+19.7%) | -$198.94 M(+3.2%) |
| Dec 2021 | -$192.73 M | -$53.83 M(+23.9%) | -$192.73 M(+7.8%) |
| Sep 2021 | - | -$43.44 M(+16.7%) | -$178.75 M(-2.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$37.21 M(-36.1%) | -$182.46 M(+3.5%) |
| Mar 2021 | - | -$58.24 M(+46.2%) | -$176.32 M(+17.8%) |
| Dec 2020 | -$149.68 M(-172.9%) | -$39.84 M(-15.5%) | -$149.68 M(+9.6%) |
| Sep 2020 | - | -$47.16 M(+51.7%) | -$136.63 M(+14.2%) |
| Jun 2020 | - | -$31.08 M(-1.7%) | -$119.61 M(+14.5%) |
| Mar 2020 | - | -$31.61 M(+18.0%) | -$104.50 M(-150.9%) |
| Dec 2019 | $205.40 M(-736.7%) | -$26.79 M(-11.1%) | $205.40 M(-9.4%) |
| Sep 2019 | - | -$30.14 M(+88.7%) | $226.78 M(-7.5%) |
| Jun 2019 | - | -$15.97 M(-105.7%) | $245.24 M(-2.7%) |
| Mar 2019 | - | $278.30 M(-5244.2%) | $252.14 M(-881.6%) |
| Dec 2018 | -$32.26 M(-7.5%) | -$5.41 M(-53.7%) | -$32.26 M(+20.1%) |
| Sep 2018 | - | -$11.69 M(+28.9%) | -$26.85 M(+77.1%) |
| Jun 2018 | - | -$9.07 M(+48.7%) | -$15.16 M(+148.7%) |
| Mar 2018 | - | -$6.10 M | -$6.10 M |
| Dec 2017 | -$34.86 M | - | - |
FAQ
- What is Adaptive Biotechnologies annual cash flow from operations?
- What is the all time high annual CFO for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies annual CFO year-on-year change?
- What is Adaptive Biotechnologies quarterly cash flow from operations?
- What is the all time high quarterly CFO for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies quarterly CFO year-on-year change?
- What is Adaptive Biotechnologies TTM cash flow from operations?
- What is the all time high TTM CFO for Adaptive Biotechnologies?
- What is Adaptive Biotechnologies TTM CFO year-on-year change?
What is Adaptive Biotechnologies annual cash flow from operations?
The current annual CFO of ADPT is -$95.21 M
What is the all time high annual CFO for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high annual cash flow from operations is $205.40 M
What is Adaptive Biotechnologies annual CFO year-on-year change?
Over the past year, ADPT annual cash flow from operations has changed by +$61.11 M (+39.09%)
What is Adaptive Biotechnologies quarterly cash flow from operations?
The current quarterly CFO of ADPT is -$12.49 M
What is the all time high quarterly CFO for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high quarterly cash flow from operations is $278.30 M
What is Adaptive Biotechnologies quarterly CFO year-on-year change?
Over the past year, ADPT quarterly cash flow from operations has changed by +$14.57 M (+53.85%)
What is Adaptive Biotechnologies TTM cash flow from operations?
The current TTM CFO of ADPT is -$95.21 M
What is the all time high TTM CFO for Adaptive Biotechnologies?
Adaptive Biotechnologies all-time high TTM cash flow from operations is $252.14 M
What is Adaptive Biotechnologies TTM CFO year-on-year change?
Over the past year, ADPT TTM cash flow from operations has changed by +$14.44 M (+13.17%)